Abeona Therapeutics (ABEO) Accounts Payables (2010 - 2026)

Abeona Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 18.87% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.1 million (down 18.87% YoY), while the FY2025 annual figure was $7.9 million, up 129.26% from the prior year.
• Accounts Payables for Q1 2026 stood at $4.1 million, down from $7.9 million in the prior quarter.
• The five-year high for Accounts Payables was $7.9 million in Q4 2025, with the low at $1.6 million in Q1 2022.
• The 5-year median for Accounts Payables is $3.1 million (2024), against an average of $3.6 million.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables sank 58.13% in 2022, then surged 136.75% in 2025.
• Abeona Therapeutics' Accounts Payables stood at $1.8 million in 2022, then advanced by 2.6% to $1.9 million in 2023, then surged by 85.2% to $3.4 million in 2024, then jumped by 129.26% to $7.9 million in 2025, then plunged by 48.4% to $4.1 million in 2026.
• Business Quant data shows ABEO's Accounts Payables at $4.1 million in Q1 2026, $7.9 million in Q4 2025, and $5.9 million in Q3 2025.